Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo
M Barok, M Tanner, K Köninki, J Isola - Breast Cancer Research, 2011 - Springer
Introduction Trastuzumab is widely used for the treatment of HER2-positive breast cancer.
Despite encouraging clinical results, a significant fraction of patients are, or become …
Despite encouraging clinical results, a significant fraction of patients are, or become …
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
TT Junttila, G Li, K Parsons, GL Phillips… - Breast cancer research …, 2011 - Springer
Trastuzumab (Herceptin®) is currently used as a treatment for patients whose breast tumors
overexpress HER2/ErbB2. Trastuzumab-DM1 (T-DM1, trastuzumab emtansine) is designed …
overexpress HER2/ErbB2. Trastuzumab-DM1 (T-DM1, trastuzumab emtansine) is designed …
Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer
Abstract Purpose: Trastuzumab-emtansine (T-DM1) is a standard treatment in advanced
HER2-positive breast cancer. However, resistance inevitably occurs. We aimed to identify …
HER2-positive breast cancer. However, resistance inevitably occurs. We aimed to identify …
Trastuzumab emtansine: mechanisms of action and drug resistance
M Barok, H Joensuu, J Isola - Breast cancer research, 2014 - Springer
Abstract Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that is effective and
generally well tolerated when administered as a single agent to treat advanced breast …
generally well tolerated when administered as a single agent to treat advanced breast …
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
Background HER2-targeting agents have dramatically changed the therapeutic landscape
of HER2+ advanced breast cancer (ABC). Within a short time frame, the rapid introduction of …
of HER2+ advanced breast cancer (ABC). Within a short time frame, the rapid introduction of …
Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)
J Diessner, V Bruttel, RG Stein, E Horn… - Cell death & …, 2014 - nature.com
The antibody trastuzumab (Herceptin) has substantially improved overall survival for
patients with aggressive HER2-positive breast cancer. However, about 70% of all treated …
patients with aggressive HER2-positive breast cancer. However, about 70% of all treated …
Resistance to trastuzumab: a necessary evil or a temporary challenge?
The aim of this review article is to examine the potential mechanisms of resistance to
trastuzumab. In the clinical setting, when trastuzumab is given as a single agent for first-line …
trastuzumab. In the clinical setting, when trastuzumab is given as a single agent for first-line …
Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells
The receptor tyrosine kinase HER2 is overexpressed in approximately 20% of breast cancer,
and its amplification is associated with reduced survival. Trastuzumab emtansine (Kadcyla …
and its amplification is associated with reduced survival. Trastuzumab emtansine (Kadcyla …
Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib
O Kalous, D Conklin, AJ Desai, NA O'Brien… - Molecular cancer …, 2012 - AACR
The human EGF (HER) family of receptors has been pursued as therapeutic targets in breast
cancer and other malignancies. Trastuzumab and lapatinib are standard treatments for …
cancer and other malignancies. Trastuzumab and lapatinib are standard treatments for …
Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells
K Köninki, M Barok, M Tanner, S Staff, J Pitkänen… - Cancer letters, 2010 - Elsevier
Trastuzumab plays an important role in breast cancer therapy. However, a significant
fraction of patients do not respond to therapy or they tend to develop resistance shortly after …
fraction of patients do not respond to therapy or they tend to develop resistance shortly after …